1. Farabaugh, S.M., Micalizzi, D.S., Jedlicka, P., Zhao, R., and Ford, H.L. (2012). Eya2 Is Required to Mediate the Pro-Metastatic Functions of Six1 Via the Induction of TGF-β Signaling, Epithelial-Mesenchymal Transition, and Cancer Stem Cell Properties. Oncogene 31: 552-562.
2. Wang, C., Jedlicka, P., Patrick, A.N., Micalizzi, D.S., Lemmer, K.C., Deitsch, E., Casas-Selves, M., Harrell, J.C., Ford, H.L. (2012). A novel pro-lymphangiogenic Six1-VEGF-C pathway mediates breast cancer metastasis. Journal of Clinical Investigation 122: 1895-1906.
Associated commentary by McCarthy, N. in Nature Cancer Reviews 12: 316. “Metastasis: SIX1 of the best”.
3. Smith, A.L., Iwanaga, R., Drasin, D.J., Micalizzi, D.S., Vartuli, R.L., Tan, A-C., and Ford, H.L. (2012). The miR106b-25 cluster targets Smad7, activates TGF-b signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 13: 5162-5171.
4. Iwanaga, R., Wang, C., Micalizzi, D.S., J.C. Harrell, Jedlicka, P., Sartorius, C., Kabos, P., Farabaugh, S., Bradford, A., Ford, H.L. (2012). The Six1 Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of ERK and TGF-b pathways. Breast Cancer Res 14: R100 (e-pub ahead of print July 5, 2012).
5. Robin, T., Smith, A.L., McKinsey, R., Reaves, L., Jedlicka*, P., Ford, H.L.* (2012). EWS/Fli1 regulates Eya3 in Ewing’s sarcoma cells via modulation of microRNAs 145 and 708, resulting in increased survival and chemoresistance. Molecular Cancer Research 10: 1098-1108. *co-corresponding authors *in research highlights for MCR issue
6. Krueger, A.B., Dehdashti, S.J., Southall, N., Marugan, J.J., Ferrer, M., Li, X., Ford, H.L., Zheng, W.*, and Zhao, R.*. (2013) High throughput screening identifies a class of specific Eya2 phosphatase inhibitors. Journal of Biomolecular Screening 18: 85-96. *co-corresponding authors.
7. Smith, A.L., Robin, T, Ford, H.L. (2012) Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy. Clinical Cancer Research18: 4514-21.
8. Patrick, A.N., Cabrera, J.H., Smith, A.L., Chen, X.S., Ford, H.L.*, and Zhao, R.* (2013). Structure-Function Analyses of the SIX1-EYA2 Complex Reveals Insights into Metastasis and BOR Syndrome. Nature Structural & Molecular Biology20: 447-453. *co-corresponding authors.
9. Auvergne, R.M., Sim, F.R., Wang, S., Chandler-Militello D., Burch, J., Al Fanek, Y., Davis, D., Benraiss, A., Walter, K., Achanta, P., Johnson, M., Quinones-Hinojosa, A., Natesan, S., Ford, H.L., and Goldman, S.A. (2013). Transcriptional Differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Reports 3: 2127-2141.
10. Cieply B, Farris J, Denvir J, Ford, H.L., and Frisch. S.M. (2013). A reciprocal feedback loop between grainyhead-like 2 and Zeb1 Controls EMT and Tumor Suppression. Cancer Research73: 6299-6309.
11. Kohrt, D., Crary, J., Zimmer, M., Patrick, A.N., Ford, H.L., Hinds, P.W., Grossel, M. J. (2013). CDK6 binds and promotes the degradation of the EYA2 protein. Cell Cycle 13: 62-71.
12. Dimberg, L.Y., Anderson, C.K., Camidge, R., Behbakht, K., Thorburn, A., Ford, H.L. (2013). On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32: 1341-1350.
13. O’Brien, J.H, Hernandez-Lagunas, L., Artinger, K.* and Ford, H.L.* (2014). MicroRNA-30a regulates zebrafish myogenesis via targeting the transcription factor Six1. Journal of Cell Science 127: 2291-301 *co-corresponding authors *Cover photo of journal
14. Krueger. A.B., Drasin, D.J., Lea, W.A., Patrick, A.N., Backos, D.S., Matheson, C.J., Hu, X., Barnaeva, E., Holliday, Blevins, M.A. , Robin, T., Eisenmesser, E., Ferrer, M., Simeonov, A., Southall, N., Reigan, P., Marugan, J.J.*, Ford, H.L.*, Zhao, R.*, (2014). Allosteric Inhibitors of the Eya2 Phosphatase Are Selective and Inhibit Eya2-mediated Cell Migration. J Biol Chem. 289: 6349-16361. *co-corresponding authors.
15. Wang, C., Harrell, J.C, Iwanaga, R., Jedlicka, P. and Ford, H.L. (2014). VEGF-C promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3 (Sod3). Breast Cancer Research16: 462.
16. Wang, C, Drasin, D.J., Pham. C., Jedlicka, P., Zaberezhnyy, V., Guney, M., Li, H., Nemenoff, R., Costello, J.C., Tan, A-K., and Ford. H.L. (2014). Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Research 74: 7357-7370.
17. Drasin, D.J., Guarnieri, A.L., Neelakantan, D., Kim. J., Gasparini, P., Cascione, L., Huebner, K., Tan, A-C., and Ford, H.L. (2015). TWIST1-induced microRNA-424 drives an intermediate epithelial-to-mesenchymal transition that opposes metastasis. Cancer Research 75: 1908-1921.
18. Towers, C.G., Guarnieri, A.L., Micalizzi, D.S., Harrell, J.C., Gillen, A.E., Kim, J., Wang, C.A., Oliphant, M.U.J., Drasin, D.J., Guney, M.A., Kabos, P., Sartorius, C.A., Tan, A-C., Perou, C.M., Espinosa, J.M., Ford, H.L. (2015). The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications 6: 10077.
19. Neelakantan, D., Drasin, D.J., and Ford, H.L. (2015). Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adhesion & Migration9: 265-276.
20. Blevins, M.A., Towers, C.G., Patrick, A.N., Zhao, R.*, and Ford, H.L.* (2015). The Six1-Eya transcriptional complex as a therapeutic target. Expert Opinion on Therapeutic Targets19:213-225. *co-corresponding authors
21. Zhou, H., Neelakantan, D., and Ford, H.L. (2016). Clonal cooperativity in heterogeneous cancers. Semin Cell Dev Biolpii: S1084-9521
22. Towers, C.G. and Ford, H.L. (2016). A tale of two ends. Cell Cycle15: 1523-1524.
23. Kendrick, A., Schafer, J., Dzieciatkowska, M., Nemkov, T., D'Alessandro, A., Neelakantan, D., Ford, H.L., Pearson, C., Weekes, C., and Hansen, K., Eisenmesser, E. (2017). CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget 8: 6742-6762.
24. Thorburn, J., Staskiewicz, L., Goodall, M.L., Dimberg, L., Frankel, A.E, Ford, H.L, and Thorburn, A. (2017). Non-cell autonomous effects of autophagy inhibition in tumor cells promote growth of drug-resistant cells. Molecular Pharmacology 91: 58-64.
25. Dimberg, L.*, Towers, C.G.*, Cabrera, J.H., Behbakht, K., Hotz, T., Kim, J., Fosmire, S., Porter, C.C., Tan, A-C., Thorburn, A., and Ford, H.L. (2017). A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Mol Cancer Res.15: 382-394. *AACR Editors Pick for April 2017
26. Tavares, A.L.P., Cox, T.C., Maxson, R.E., Ford, H.L., and Clouthier, D.E. (2017). Negative Regulation of Endothelin signaling by SIX1 is required for proper maxillary development. Development 144: 2021- 2031.
27. Neelakantan, D., Zhou, H., Oliphant, M.U.J., Zhang, X., Simon, L.M., Henke, D.M., Shaw, C.A., Wu, M- F., Hilsenbeck, S.G., White, L.D., Lewis, M.T., and Ford, H.L. (2017). EMT Cells Increase Breast Cancer Metastasis via Paracrine GLI Activation in Neighbouring Tumour Cells. Nature Communications 8: 15773.
28. Zhou, H., Zhang, L., Vartuli, R.L., Ford, H.L., and Zhao, R. (2018). The Eya Phosphatase: Its Unique Role in Cancer. International Journal of Biochemistry and Cell Biology 96: 165-170.
29. Vartuli, R.L., Zhou, H., Zhang, L., Powers, R.K., Klarquist, J., Rudra, P., Vincent, M.Y., Ghosh, D., Costello, J.C., Kedl, R.M., Slansky, J.E., Zhao, R., and Ford, HL. (2017). Eya3 Enhances Breast Cancer Progression via Threonine Phosphatase Mediated Upregulation of PD-L1 and Resultant Immune Suppression. Journal of Clinical Investigation 128: 2535-2550. Highlighted in Cancer Discovery 8: OF8.
30. Zhang, L.#, Zhou, H.#, Li, X., Vartuli, R., Rowse, M., Xing, Y., Rudra, P., Ghosh, D., Zhao, R.*, Ford, H.L.* (2018). Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications 9: 1047. #co-first authors, *co-corresponding authors
31. Guarnieri A.L.#, Towers C.G.#, Drasin D.J., Oliphant M.U.J., Hotz T., Vartuli R.L., Linklater E., Pandey A., Espinosa J.M., and Ford H.L. (2018). The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37: 3879-3893. #co-first authors